Prahlad V. Raninga

1.0k total citations
25 papers, 742 citations indexed

About

Prahlad V. Raninga is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Prahlad V. Raninga has authored 25 papers receiving a total of 742 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 9 papers in Oncology and 5 papers in Hematology. Recurrent topics in Prahlad V. Raninga's work include Redox biology and oxidative stress (10 papers), Ubiquitin and proteasome pathways (4 papers) and Cancer-related Molecular Pathways (4 papers). Prahlad V. Raninga is often cited by papers focused on Redox biology and oxidative stress (10 papers), Ubiquitin and proteasome pathways (4 papers) and Cancer-related Molecular Pathways (4 papers). Prahlad V. Raninga collaborates with scholars based in Australia, Taiwan and United Kingdom. Prahlad V. Raninga's co-authors include Kathryn F. Tonissen, Giovanna Di Trapani, Slavica Vučković, Kum Kum Khanna, Murugan Kalimutho, Debottam Sinha, Kristian M. Bowles, David J. MacEwan, Stuart A. Rushworth and Deepak Mittal and has published in prestigious journals such as Cancer Research, Oncogene and International Journal of Molecular Sciences.

In The Last Decade

Prahlad V. Raninga

24 papers receiving 738 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Prahlad V. Raninga Australia 15 533 175 115 79 78 25 742
Xiaoying Lan China 15 461 0.9× 227 1.3× 77 0.7× 95 1.2× 40 0.5× 20 699
Xianping Shi China 20 683 1.3× 261 1.5× 148 1.3× 154 1.9× 71 0.9× 35 1.0k
Filippa Pettersson Canada 18 654 1.2× 220 1.3× 96 0.8× 73 0.9× 90 1.2× 26 884
Jidong Zhu China 14 752 1.4× 146 0.8× 106 0.9× 65 0.8× 95 1.2× 34 1.1k
Lynn Ueno United States 9 630 1.2× 221 1.3× 148 1.3× 52 0.7× 126 1.6× 13 910
Nengming Lin China 19 569 1.1× 221 1.3× 173 1.5× 35 0.4× 72 0.9× 55 870
Miljan Kuljanin United States 15 781 1.5× 257 1.5× 135 1.2× 26 0.3× 63 0.8× 30 1.1k
Guillaume Pinna France 17 647 1.2× 169 1.0× 193 1.7× 25 0.3× 80 1.0× 40 1.0k
Sumeer Dhar Sweden 17 450 0.8× 273 1.6× 85 0.7× 38 0.5× 69 0.9× 28 780
Enrica Favini Italy 16 450 0.8× 180 1.0× 100 0.9× 30 0.4× 38 0.5× 23 668

Countries citing papers authored by Prahlad V. Raninga

Since Specialization
Citations

This map shows the geographic impact of Prahlad V. Raninga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Prahlad V. Raninga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Prahlad V. Raninga more than expected).

Fields of papers citing papers by Prahlad V. Raninga

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Prahlad V. Raninga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Prahlad V. Raninga. The network helps show where Prahlad V. Raninga may publish in the future.

Co-authorship network of co-authors of Prahlad V. Raninga

This figure shows the co-authorship network connecting the top 25 collaborators of Prahlad V. Raninga. A scholar is included among the top collaborators of Prahlad V. Raninga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Prahlad V. Raninga. Prahlad V. Raninga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Raninga, Prahlad V., Bijun Zeng, Davide Moi, et al.. (2024). CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers. Oncogene. 44(13). 893–908. 2 indexed citations
2.
Sinclair, Paul, Prahlad V. Raninga, Sarra Ryan, et al.. (2023). Disruption to the FOXO-PRDM1 axis resulting from deletions of chromosome 6 in acute lymphoblastic leukaemia. Leukemia. 37(3). 636–649. 4 indexed citations
3.
Raninga, Prahlad V., et al.. (2023). A design of experiments screen reveals that Clostridium novyi-NT spore germinant sensing is stereoflexible for valine and its analogs. Communications Biology. 6(1). 118–118. 6 indexed citations
4.
Raninga, Prahlad V., Yaowu He, Keshava K. Datta, et al.. (2022). Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in MYC-high high-grade serous ovarian carcinoma. Molecular Therapy. 31(3). 729–743. 18 indexed citations
5.
Lu, Xue, Yaowu He, Rebecca L. Johnston, et al.. (2022). CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors. Journal of Experimental & Clinical Cancer Research. 41(1). 355–355. 6 indexed citations
6.
Raninga, Prahlad V., et al.. (2021). Correction: Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myeloma. Oncotarget. 12(9). 948–949.
7.
Raninga, Prahlad V., Andy Lee, Debottam Sinha, et al.. (2020). Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition. Theranostics. 10(12). 5259–5275. 52 indexed citations
8.
Wang, Sicong, et al.. (2020). Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment. Antioxidants. 9(3). 207–207. 14 indexed citations
9.
Sinha, Debottam, Purba Nag, Devathri Nanayakkara, et al.. (2020). Cep55 overexpression promotes genomic instability and tumorigenesis in mice. Communications Biology. 3(1). 593–593. 24 indexed citations
10.
Kim, Seong‐Jin, Myoung Hee Kang, Ji Eun Won, et al.. (2020). RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC. Theranostics. 10(18). 7974–7992. 53 indexed citations
11.
Kalimutho, Murugan, Debottam Sinha, Deepak Mittal, et al.. (2019). Blockade of PDGFRβ circumvents resistance to MEK-JAK inhibition via intratumoral CD8+ T-cells infiltration in triple-negative breast cancer. Journal of Experimental & Clinical Cancer Research. 38(1). 85–85. 14 indexed citations
12.
Raninga, Prahlad V., et al.. (2019). Synergistic anti-cancer activity of auranofin with anti-PD-L1 therapy in triple negative breast cancer. Annals of Oncology. 30. v3–v3. 3 indexed citations
13.
Raninga, Prahlad V., Kyohei Nakamura, Mika Casey, et al.. (2019). Anticancer activity of a Gold(I) phosphine thioredoxin reductase inhibitor in multiple myeloma. Redox Biology. 28. 101310–101310. 51 indexed citations
14.
Kalimutho, Murugan, Debottam Sinha, Jessie Jeffery, et al.. (2018). CEP 55 is a determinant of cell fate during perturbed mitosis in breast cancer. EMBO Molecular Medicine. 10(9). 63 indexed citations
15.
Raninga, Prahlad V., Giovanna Di Trapani, & Kathryn F. Tonissen. (2017). The Multifaceted Roles of DJ-1 as an Antioxidant. Advances in experimental medicine and biology. 1037. 67–87. 53 indexed citations
16.
Raninga, Prahlad V., Giovanna Di Trapani, Slavica Vučković, & Kathryn F. Tonissen. (2016). TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition. Cell Cycle. 15(4). 559–572. 47 indexed citations
17.
Raninga, Prahlad V., Giovanna Di Trapani, Slavica Vučković, & Kathryn F. Tonissen. (2016). Targeted knockdown of DJ-1 induces multiple myeloma cell death via KLF6 upregulation. APOPTOSIS. 21(12). 1422–1437. 16 indexed citations
18.
Lovitt, Carrie J., et al.. (2016). Expression of the thioredoxin system in an in vivo-like cancer cell environment upon auranofin treatment. European Journal of Cell Biology. 95(10). 378–388. 4 indexed citations
19.
Raninga, Prahlad V., Giovanna Di Trapani, Slavica Vučković, & Kathryn F. Tonissen. (2016). Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma. Redox Biology. 8. 175–185. 43 indexed citations
20.
Rushworth, Stuart A., Kristian M. Bowles, Prahlad V. Raninga, & David J. MacEwan. (2010). NF-κB–Inhibited Acute Myeloid Leukemia Cells Are Rescued from Apoptosis by Heme Oxygenase-1 Induction. Cancer Research. 70(7). 2973–2983. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiaoying Lan Breakdown of academic impact, for papers by Xianping Shi Breakdown of academic impact, for papers by Filippa Pettersson Breakdown of academic impact, for papers by Jidong Zhu Breakdown of academic impact, for papers by Lynn Ueno Breakdown of academic impact, for papers by Nengming Lin Breakdown of academic impact, for papers by Miljan Kuljanin Breakdown of academic impact, for papers by Guillaume Pinna Breakdown of academic impact, for papers by Sumeer Dhar Breakdown of academic impact, for papers by Enrica Favini
Rankless by CCL
2026